Recombinant multi-species BARD1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BARD1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
This gene encodes a protein which interacts with the N-terminal region of BRCA1. In addition to its ability to bind BRCA1 in vivo and in vitro, it shares homology with the 2 most conserved regions of BRCA1: the N-terminal RING motif and the C-terminal BRCT domain. The RING motif is a cysteine-rich sequence found in a variety of proteins that regulate cell growth, including the products of tumor suppressor genes and dominant protooncogenes. This protein also contains 3 tandem ankyrin repeats. The BARD1/BRCA1 interaction is disrupted by tumorigenic amino acid substitutions in BRCA1, implying that the formation of a stable complex between these proteins may be an essential aspect of BRCA1 tumor suppression. This protein may be the target of oncogenic mutations in breast or ovarian cancer. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2013]
The Alternative Names of target: BARD-1,BARD1,BRCA1-associated RING domain protein 1,Bard1,RING-type E3 ubiquitin transferase BARD1

Target products collectionGo to BARD1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IO013-Ag-1/ GM-Tg-hg-IO013-Ag-2 Human BARD1 protein Human
GM-Tg-rg-IO013-Ag-1/ GM-Tg-rg-IO013-Ag-2 Rat BARD1 protein Rat
GM-Tg-mg-IO013-Ag-1/ GM-Tg-mg-IO013-Ag-2 Mouse BARD1 protein Mouse
GM-Tg-cynog-IO013-Ag-1/ GM-Tg-cynog-IO013-Ag-2 Cynomolgus/Rhesus macaque BARD1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IO013-Ag-1/ GM-Tg-felg-IO013-Ag-2 Feline BARD1 protein Feline
GM-Tg-cang-IO013-Ag-1/ GM-Tg-cang-IO013-Ag-2 Canine BARD1 protein Canine
GM-Tg-bovg-IO013-Ag-1/ GM-Tg-bovg-IO013-Ag-2 Bovine BARD1 protein Bovine
GM-Tg-equg-IO013-Ag-1/ GM-Tg-equg-IO013-Ag-2 Equine BARD1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IO013-Ag-1/ GM-Tg-hg-IO013-Ag-2; GM-Tg-rg-IO013-Ag-1/ GM-Tg-rg-IO013-Ag-2;
GM-Tg-mg-IO013-Ag-1/ GM-Tg-mg-IO013-Ag-2; GM-Tg-cynog-IO013-Ag-1/ GM-Tg-cynog-IO013-Ag-2;
GM-Tg-felg-IO013-Ag-1/ GM-Tg-felg-IO013-Ag-2; GM-Tg-cang-IO013-Ag-1/ GM-Tg-cang-IO013-Ag-2;
GM-Tg-bovg-IO013-Ag-1/ GM-Tg-bovg-IO013-Ag-2; GM-Tg-equg-IO013-Ag-1/ GM-Tg-equg-IO013-Ag-2
Products Name BARD1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name BARD1
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BARD1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.